Ratings Glenmark Pharmaceuticals Limited

Equities

GLENMARK

INE935A01035

Delayed NSE India S.E. Other stock markets 05:56:12 2024-04-25 am EDT			5-day change	1st Jan Change
1,081 ^INR	+0.92%		+3.71%	+26.52%

Apr. 01	Glenmark Pharmaceuticals Limited Announces Board Changes	CI
Mar. 12	Nirma Limited completed the acquisition of 75% stake in Glenmark Life Sciences Limited from Glenmark Pharmaceuticals Limited.	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.
Analyst opinion has improved significantly over the past four months.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 42.25 times its estimated earnings per share for the ongoing year.
The company appears highly valued given the size of its balance sheet.
The valuation of the company is particularly high given the cash flows generated by its activity.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
GLENMARK PHARMACEUTICALS LIMITED	+26.52%	3.63B		B-
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.87%	42.78B		B-
OTSUKA HOLDINGS CO., LTD.	+18.59%	22.25B		B+
SANDOZ GROUP AG	+14.67%	14.39B		-
CIPLA LIMITED	+12.66%	13.55B		B+
ZYDUS LIFESCIENCES LIMITED	+38.14%	11.27B		B
ONO PHARMACEUTICAL CO., LTD.	-9.80%	6.95B		B+
THE MEDICINES COMPANY	-0.05%	6.79B	-	-
STADA ARZNEIMITTEL	-8.87%	5.73B	-	-
ASPEN PHARMACARE HOLDINGS LIMITED	+6.29%	5.01B		B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes